Kenneth P. Madden - Researcher Profile

Publications

2 shown

Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset

Wayne M. Clark , S. Wissman , Gregory W. Albers +4 more

This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treat...

1999 JAMA 1181 citations

The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)

Wayne M. Clark , Gregory W. Albers , Kenneth P. Madden +1 more

Background and Purpose —The Thrombolytic Therapy in Acute Ischemic Stroke Study, which started in August of 1991, was designed to assess the efficacy and safety of intravenous r...

2000 Stroke 415 citations

Frequent Co-Authors

Wayne M. Clark

Oregon Health & Science University

S. Wissman

for the ATLANTIS Study Investigators

Researcher Info

h-index: 2
Publications: 2
Citations: 1,596
Institution: Marshfield Clinic

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.